Nutraceuticals and dyslipidaemia: beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello, PA Modesti… - Journal of functional …, 2014 - Elsevier
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …
被引用次数：380 相关文章

[引用][C] Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello… - Journal of Functional …, 2014 - cir.nii.ac.jp
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello, P Modesti… - JOURNAL OF …, 2014 - arpi.unipi.it
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …
[PDF] academia.edu

[PDF][PDF] Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitanoa, M Camelib, M Maielloc, PA Modestid… - 2013 - academia.edu
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello, PA Modesti… - Journal of Functional …, 2014 - infona.pl
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …

Nutraceuticals and dyslipidaemia: beyond the common therapeutics.

P Scicchitano, M Cameli, M Maiello, PA Modesti… - 2014 - cabidigitallibrary.org
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …

[引用][C] Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello… - JOURNAL OF …, 2013 - ricerca.uniba.it
Nutraceuticals and dyslipidaemia: Beyond the common therapeutics IRIS IRIS Home Sfoglia
Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano English English LOGIN …

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitano, M Cameli, M Maiello… - JOURNAL OF …, 2014 - flore.unifi.it
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …
[PDF] archive.org

[PDF][PDF] Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitanoa, M Camelib, M Maielloc, PA Modestid… - 2013 - scholar.archive.org
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …
[PDF] academia.edu

[PDF][PDF] Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

P Scicchitanoa, M Camelib, M Maielloc, PA Modestid… - 2013 - academia.edu
Dyslipidaemia accelerates the atherosclerotic process and its morbid consequences; statins
represent the evidence-based treatment of choice for reducing low-density lipoprotein …